1. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984; 129: 211–5.
2. Lu Q, Yang J, Liu Z et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184: 106–15.
3. Miller DD, Amin MM, Palmer LB et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003; 168: 1205–9.
4. Clark R, Heslet L, Abtonsen K, Donehower B. Evaluation of the disposition and safety of tobramycin solution for inhlalation in ventilator associated pneumonia or tracheobronchitis patients (poster). Presented at American Thoracic Society International Conference 2003. Seattle, WA.
5. Niederman MS, Chastre J, Corkery K et al. Bay 41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012; 38: 263–71.
6. Montgomery AB, Vallance S, Abuan T et al. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow Inline nebulizer system in mechanically ventilated patients (abstr. 42767 and poster 42767). Am J Respir Crit Care Med 2013; 187: A3236.
7. Van Devanter DR, Rose LM, Sprugel KH. 28-day inhalation toxicology of polymyxin E1, the major active component of colistin, in rats and dogs (poster P-236). Presented at European Cystic Fibrosis Congress June 6–9, 2001. Vienna, Austria.
8. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 2007; 357: 2310–1.
9. Mendelman PM, Smith AL, Levy J et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761–5.
10. Montgomery AB, Rhomberg P, Abuan T, Jones R. Synergistic effects for a combination of amikacin and fosfomycin against selected resistant Gram-negative pathogens (abstr. 43023 and poster). Am J Respir Crit Care Med 2013; 187: A3236.
11. McCoy KS, Quittner AL, Oermann CM et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921–8.
12. Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135: 1223–32.
13. Oermann CM, Retsch-Bogart GZ, Quittner AL et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121–34.
14. Hilas O, Ezzo DC, Jodlowski TZ. Doripenem (doribax), a new carbapenem antibacterial agent. Pharm Ther 2008; 33: 134–80.
15. Sorbello A. Doripenem safety review 2013.
16. MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64: 829–36.
17. Trapnell BC, McColley SA, Kissner DG et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185: 171–8.
18. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther 2011; 28: 728–47.
19. Wood GC. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011; 9: 993–1000.
20. Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012; 57: 1226–33.
21. Lu Q, Luo R, Bodin L et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012; 117: 1335–47.
22. Zhanel GG, Adam HJ, Low DE et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis 2011; 69: 291–306.
23. Alvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 689–90.

В.Б.Белобородов

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва